Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

37.5%

6 terminated/withdrawn out of 16 trials

Success Rate

53.8%

-32.7% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 recruiting2 with results4 withdrawn

Enrollment Performance

Analytics

Phase 1

8(72.7%)

Phase 2

2(18.2%)

N/A

1(9.1%)

11Total

Phase 1(8)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT07543757Recruiting

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

Role: collaborator

NCT05740280Phase 1Terminated

iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects

Role: collaborator

NCT06008457Completed

Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit

Role: collaborator

NCT05697198Completed

PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

Role: lead

NCT05176665Phase 1Recruiting

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Role: collaborator

NCT04364269Phase 2Completed

Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia

Role: collaborator

NCT04566653Completed

Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

Role: collaborator

NCT05063357Phase 1Withdrawn

131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

Role: collaborator

NCT05498389Phase 1Unknown

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Role: collaborator

NCT05832775Phase 1Withdrawn

Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's

Role: collaborator

NCT05222165Phase 1Withdrawn

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Role: collaborator

NCT05511558Phase 1Completed

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

Role: collaborator

NCT05642546Phase 1Completed

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

Role: collaborator

NCT04938635Phase 2Withdrawn

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Role: collaborator

NCT03645785Not ApplicableCompleted

Variation in Urine Electrolytes, pH and Specific Gravity Throughout the Day

Role: collaborator

NCT00581178Terminated

Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation

Role: collaborator

All 16 trials loaded